Related Experiment Video
Updated: Oct 11, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
[Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia]
1Pro Pracovní skupinu dĕtské hematologie v CR CLIP-Childhood Leukaemia Investigation Prague.
Insights
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia predicts outcomes. Low levels indicate better prognosis, while higher levels correlate with increased relapse risk.
Area of Science:
- Pediatric Hematology
- Oncology
- Immunology
Context:
- Minimal residual disease (MRD) is a critical prognostic indicator in childhood acute lymphoblastic leukemia (ALL).
- The end of induction therapy is a key time point for predicting treatment success.
- A pilot study in the Czech Republic analyzed 51 pediatric ALL patients.
Purpose:
- To assess the prognostic value of MRD levels at the end of induction therapy in childhood ALL.
- To stratify patients into risk groups based on MRD levels.
- To compare findings with established BFM group protocols.
Summary:
- The study utilized a method detecting clonal rearrangements of immuno-receptor genes to measure MRD.
- 63% of patients (32/51) showed low or undetectable MRD levels.
- 10% of patients (5/51) had high MRD levels, indicating a higher risk of relapse, with relapse rates of 3%, 7%, and 20% in different risk subgroups.
Impact:
- This pilot study supports the integration of MRD monitoring into new BFM treatment protocols for risk-based stratification.
- Early identification of high-risk patients can potentially lead to tailored treatment strategies.
- Findings contribute to refining prognostic models for childhood ALL.
Abstract:
The level of minimal residual disease is an important prognostic factor in childhood acute lymphoblastic leukaemia. The end of induction therapy is the most significant time-point for prediction of treatment outcome. Within a pilot study covered by the Paediatric Haematology Working Group in the Czech Republic 51 childhood patients were analysed at diagnosis of acute lymphoblastic leukaemia and at the end of induction using method based on detection of clonal rearrangements of immuno-receptor genes. The majority of tested patients (32/51, 63%) had a low or non-detectable levels of residual disease, a group of patients with the highest levels and thus the highest risk of relapse included 10% of patients (5/51). Within each of three risk groups one patient has relapsed so far. Therefore, the relapse rate in particular subgroups is 3% (1/32), 7% (1/14) and 20% (1/5) to date, respectively. The results are compared with these published by the BFM group (van Dongen et al., Lancet 1998). The pilot phase of a new BFM treatment protocols includes examination of residual disease for stratification of patients into the different risk groups.
